FIELD: biotechnology; immunology.
SUBSTANCE: disclosed is a humanised antibody and its antigen-binding fragment specifically binding to folic acid receptor 1 (FOLR1) and characterized by amino acid sequences of sections, determining complementarity with antigen (CDR). Also disclosed is a method of producing a humanised antibody according to the invention; immunoconjugates with a cytotoxic agent; pharmaceutical compositions; diagnostic composition; sets; methods for inhibiting tumor growth and a method of treating cancer. Disclosed are isolated polynucleotides encoding the antibody variable domains under the invention; containing vectors and host cells.
EFFECT: antibody according to the invention can find further application in therapy of diseases characterized by high expression of FOLR1.
55 cl, 4 tbl, 19 ex, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DETECTING FOLATE RECEPTOR 1 IN PATIENT SAMPLE | 2018 |
|
RU2759410C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| DIAGNOSTIC ANALYSES AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2018 |
|
RU2788126C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
